Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Healthcare Biotechnology
Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Liminal BioSciences Inc.
Bullboard Posts
User Avatar Image
(33)
•••
Comment by Biofinderon Jul 25, 2018 9:20am
177 Views
Post# 28363666

RE:RE:Joe Parker, MD discusses pbi-450 trial for IPF patients

RE:RE:Joe Parker, MD discusses pbi-450 trial for IPF patients
funkshow wrote: Thanks for the repost Bio but the fact remains that the IPF was suppose to start in July - what’s the excuse as to why it has not started?

incompetent management team and the fact that I believe PL wanted to wait and partner 4050 AFTER the additional Alstrom data was gathered from the phase 2 trial, which did in fact attract additional interested potential 4050 partners, inwhich after a deal is is signed will fund the upcoming IPF phase 3 IPF trial, pay PLI upfront money, and pay PLI milestones payments.


Bullboard Posts
Dealroom for high-potential pre-IPO opportunities